Author: Abdul Rahim J
College: Government law college,salem]l
LinkedIn Profile: https://www.linkedin.com/in/abdul-rahim-9743b6342?utm_source=share_via&utm_content=profile&utm_medium=member_android
To the Point
The present case concerns a patent application filed by Novartis AG for “Glivec,” the beta crystalline form of imatinib mesylate, a drug used in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumours. The Indian Patent Office rejected the application in 2006, holding that the compound was merely a new form of a known substance, imatinib, which had already been disclosed in an earlier patent (the Zimmermann patent) and did not demonstrate enhanced therapeutic efficacy as required under Section 3(d) of the Patents Act, 1970. Novartis unsuccessfully challenged this rejection before the Intellectual Property Appellate Board and subsequently approached the Supreme Court of India by way of special leave. The Supreme Court delivered its judgment on 1 April 2013, dismissing Novartis’s appeals and affirming that the beta crystalline form of imatinib mesylate did not qualify for patent protection in India.
Use of Legal Jargon
At the heart of the dispute lay Section 3(d) of the Patents Act, 1970, a provision inserted through the 2005 amendment that brought Indian patent law into conformity with the TRIPS Agreement while simultaneously guarding against the practice known as “evergreening,” whereby originator pharmaceutical companies seek successive patents on marginal variations of an already known molecule to extend market exclusivity beyond the standard twenty-year term. Section 3(d) excludes from patentability the mere discovery of a new form of a known substance unless that new form results in a significant enhancement of known efficacy, and it deems salts, esters, polymorphs, metabolites and analogous derivatives to be the same substance unless they differ significantly in properties with regard to efficacy. Novartis contended that the beta crystalline form exhibited superior bioavailability and improved physico-chemical properties, including better flow characteristics, thermodynamic stability and lower hygroscopicity, and argued that these attributes constituted enhanced efficacy sufficient to satisfy the statutory threshold. The Court, however, drew a sharp distinction between physical efficacy and therapeutic efficacy, holding that in the case of a pharmaceutical substance, efficacy under Section 3(d) means therapeutic efficacy alone, that is, the capacity of the drug to produce a desired curative effect in the patient. Improved solubility or bioavailability, the Bench reasoned, would qualify only if the patentee could demonstrate that such properties directly and demonstrably translated into a greater therapeutic benefit, a burden Novartis failed to discharge on the evidentiary record. The judgment also engaged with the doctrine of prior art and anticipation, examining whether the beta crystalline form was already disclosed or rendered obvious by the earlier Zimmermann patent, and invoked principles of purposive statutory interpretation to read Section 3(d) in light of Parliament’s stated intent, drawn from the Ayyangar Committee Report and subsequent legislative debates, to prevent frivolous patenting and to preserve access to affordable medicines. The Court further situated its reasoning within India’s obligations under the TRIPS Agreement and the Doha Declaration on the TRIPS Agreement and Public Health, holding that Section 3(d) was a TRIPS-compliant flexibility available to member states seeking to balance intellectual property protection with public health imperatives, rather than an impermissible additional hurdle to patentability.
The Proof
The Supreme Court’s ruling in Novartis carries significance far beyond the fate of a single patent application. By construing efficacy strictly to mean therapeutic efficacy, the judgment closed a door through which pharmaceutical companies might otherwise have secured incremental patents on trivial reformulations, thereby delaying the entry of generic competitors and keeping essential medicines priced beyond the reach of ordinary patients. The decision affirmed that Indian patent law, while compliant with international obligations, retains the sovereign latitude to design safeguards suited to a developing economy with a large population dependent on affordable generic drugs. It reassured India’s generic pharmaceutical industry, often described as the “pharmacy of the developing world,” that legitimate innovation would continue to be rewarded while evergreening strategies would not. The judgment also demonstrated the judiciary’s willingness to apply exacting scientific and evidentiary scrutiny to patent claims, insisting that assertions of improved efficacy be substantiated by rigorous comparative data rather than broad assertions of technical superiority. In doing so, the Court signalled to future patent applicants, patent offices and appellate bodies that Section 3(d) is not a mere formality but a substantive filter requiring cogent proof.
Abstract
In Novartis AG v. Union of India, the Supreme Court of India was called upon to decide whether the beta crystalline form of imatinib mesylate, marketed as Glivec, qualified for patent protection under the Patents Act, 1970, as amended in 2005. Novartis argued that the compound’s improved bioavailability and stability amounted to enhanced efficacy within the meaning of Section 3(d), while the Union of India, along with generic manufacturers and public health advocates who had been permitted to intervene, argued that the claimed improvements were merely incidental physical properties that did not translate into any additional therapeutic benefit for patients. The Court held that efficacy under Section 3(d), in the context of pharmaceutical substances, must be understood as therapeutic efficacy, and since Novartis had not established any such enhancement over the known compound, the beta crystalline form did not merit a separate patent. The appeals were accordingly dismissed, and the rejection of the patent application was upheld, reaffirming Section 3(d) as a constitutionally and internationally valid check against evergreening.
Case Laws
1. F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (2012, Delhi High Court)
This case involved a patent infringement dispute over the lung cancer drug Tarceva (erlotinib), where the originator sought an injunction against a generic manufacturer. The Delhi High Court declined to grant an interim injunction, holding that public interest in access to an affordable, life-saving medicine outweighed the patentee’s claim, a balancing exercise that mirrors the public health rationale later reinforced in Novartis.
2. Bayer Corporation v. Union of India (2014, Bombay High Court)
Arising from India’s first compulsory licence, granted to Natco Pharma for the anti-cancer drug Nexavar (sorafenib), the Bombay High Court upheld the licence on the ground that the patented drug was not available to the public at a reasonably affordable price. The decision, like Novartis, affirmed that patent rights in the pharmaceutical sector must yield to legitimate public health considerations.
3. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019, Supreme Court of India)
This case examined the patentability of genetically modified Btcotton technology and the scope of exclusions under the Patents Act. The Court’s insistence on a strict, textual reading of statutory exclusions from patentability echoes the approach taken in Novartis, where the beta crystalline form was tested rigorously against the precise wording of Section 3(d).
4. Natco Pharma Ltd. v. Union of India (2013, Intellectual Property Appellate Board)
Decided in the aftermath of the Bayer compulsory licensing dispute, this case further developed the jurisprudence on balancing patent exclusivity with affordable access to medicines, building upon the public interest foundation that the Supreme Court had articulated in Novartis earlier the same year.
Conclusion
(a) The Supreme Court held that the beta crystalline form of imatinib mesylate did not satisfy the requirement of enhanced therapeutic efficacy under Section 3(d) of the Patents Act, 1970. (b) Novartis’s patent application for Glivec was accordingly rejected, and the order of the Intellectual Property Appellate Board was upheld. (c) Section 3(d) was declared a valid and TRIPS-compliant safeguard against the evergreening of pharmaceutical patents, falling squarely within the flexibilities recognised under the Doha Declaration. (d) The ruling preserved the availability of affordable generic versions of imatinib mesylate for patients in India and, given India’s role as a major generic drug supplier, for patients in other developing countries as well. All appeals were disposed of in the above terms.
FAQs
Why did the Supreme Court reject Novartis’s patent application for Glivec?
The Court found that the beta crystalline form of imatinib mesylate was merely a new form of an already known substance and that Novartis failed to prove that this new form produced any significantly enhanced therapeutic effect, as required by Section 3(d) of the Patents Act, 1970. Improved solubility or stability alone was held insufficient without demonstrated therapeutic benefit.
What is “evergreening” and why does Indian law guard against it?
Evergreening refers to the practice of seeking new patents on minor modifications of an existing drug to prolong market exclusivity beyond the original patent term. Indian law, through Section 3(d), guards against this practice to prevent monopolistic pricing on essential medicines and to preserve timely access to affordable generic alternatives for patients.
